No Data
No Data
Alnylam Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment
FDA Approves Sanofi's Hemophilia Drug
Alnylam Pharmaceuticals Analyst Ratings
Express News | Alnylam Pharmaceuticals Inc : Scotiabank Raises Target Price to $342 From $338